Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00251446 · ClinicalTrials.gov registry record · Phase 2
A Phase II Single Arm Trial of Single-agent Vinflunine as Second-line Treatment of Advanced Non-Small Cell Lung Cancer
A Phase 2 study, sponsored by Veeda Oncology.
- Completed
- Registry status
- Phase 2
- Development phase
- 70
- Enrollment target
NCT00251446 is a Phase 2 study that has completed, run by Veeda Oncology. The registered enrollment target is 70 participants.
The verdict
NCT00251446, a Phase 2 study, has completed, sponsored by Veeda Oncology.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 70 participants
- Enrollment target
Study Summary
This is a Phase II, single-arm study in patients with stage IIIB (with malignant pleural effusion) and IV NSCLC who have been previously treated with a platinum-based doublet. Each cycle will be 21 days. On Day 1 of each cycle, patients will receive vinflunine 320 mg/m2 as a 20-minute IV infusion. Patients will continue to receive study treatment until disease progression or unacceptable toxicity. Patients will be evaluated every 2 cycles for response using RECIST criteria.
Interventions
- DRUG Vinflunine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 70 participants |
| Start Date | 2005-10 |
| Est. Completion | 2008-03 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00251446
The ClinicalTrials.gov registry entry for NCT00251446 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 70 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Veeda Oncology, which has 9 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Vinflunine is the first listed.
NCT00251446 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00251446 about?
NCT00251446 is a clinical study titled "A Phase II Single Arm Trial of Single-agent Vinflunine as Second-line Treatment of Advanced Non-Small Cell Lung Cancer". This is a Phase II, single-arm study in patients with stage IIIB (with malignant pleural effusion) and IV NSCLC who have been previously treated with a platinum-based doublet. Each cycle will be 21 days. On Day 1 of each cycle, patients will receive vinflunine 320 mg/m2 as a 20-minute IV infusion. ...
What is the current status of trial NCT00251446?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 70 participants. The study started on 2005-10. Estimated completion is 2008-03.
What interventions are being tested in trial NCT00251446?
The interventions under investigation include: Vinflunine (DRUG).
Who is sponsoring clinical trial NCT00251446?
This trial is sponsored by Veeda Oncology, which has 9 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.